News and Press Releases
Our quarterly newsletter is packed full of the latest ion channel news and reviews. We cover events, webinars, research findings, and publications and insights from our team, partners, and distinguished guests. Receive the latest ion channel, cardiac safety and neuroscience news and insights to your inbox.
2023
Metrion Biosciences closes £3.7m new equity financing
20th December 2023
Metrion Biosciences announces launch of Good Laboratory Practice (GLP) hERG Testing Service
1st August 2023
Metrion Biosciences expands senior leadership team with appointments of Dr Robert Kirby as COO and Dr Edward Stevens as CSO
6th July 2023
Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US Operations
12th June 2023
2022
Metrion Biosciences and the KCNC1 Foundation collaborate on development of new ion channel modulators for ultra-rare genetic disorder
7th December 2022
Metrion Biosciences invests in new High Throughput Screening capability and expanded facilities
30th November 2022
Metrion Biosciences appoints Dr Benedetta Montagnini as head of European Business Development
9th June 2022
2021
Metrion Biosciences and Bioqube Ventures collaborate on venture creation project to identify novel ion channel inhibitors for autoimmune diseases
16 December 2021
Metrion Biosciences expands ion channel drug discovery service capabilities and in-house expertise
07 December 2021
Metrion Biosciences appoints Dr Rory Curtis as Vice President, US Commercial Operations
30 November 2021
Metrion Biosciences expands into new headquarters to support continued growth
22 September 2021
Metrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development
26 July 2021
Metrion Biosciences appoints Mark Keogh as Non-Executive Director
19th April 2021
Metrion Biosciences closes £2.7m new equity financing
6th April 2021
Metrion Biosciences appoints John Montana as Non-Executive Director
9th February 2021
Metrion Biosciences and Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration
1st February 2021
Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaboration
18th January 2021
2019
Metrion Biosciences and LifeArc extend ion channel drug discovery collaboration to accelerate neuroscience-focused research
3rd December 2019
Metrion Biosciences appoints Dr Andrew Southan as Chief Executive Officer
8th April 2019
Metrion Biosciences closes funding round
1st April 2019
Metrion Biosciences and LifeArc sign collaboration agreement for neuroscience-focused ion channel drug discovery
29th January 2019
2018
Metrion Biosciences makes senior appointments to strengthen its drug discovery leadership team
17th September 2018
Metrion Biosciences and AMRI collaborate to offer ion channel drug discovery services
5th September 2018
Metrion awarded £637k Innovate UK Biomedical Catalyst primer award
28th August 2018
Metrion appoints two new Board Directors
5th March 2018
Metrion Biosciences awarded £200k funding under Innovate UK Biomedical Catalyst Feasibility Award
5th February 2018
Metrion Biosciences acquires rights to small molecule potassium channel inhibitors from Japan Tobacco Inc
29th January 2018
Metrion Biosciences opens £600k investment round through SyndicateRoom to support growth of service business
16th January 2018
2017
LifeArc and Metrion Biosciences extend partnership to support LifeArc’s neuroscience small molecule drug discovery programme
31st July 2017
Metrion Biosciences appoints Chief Operating Officer and Head of Business Development
2nd May 2017
Metrion Biosciences and Venomtech announce collaboration to search for novel modulators of ion channels with proven therapeutic potential
24th April 2017
Metrion Biosciences and Concept Life Sciences Introduce Integrated Ion Channel Drug Discovery Service
15th March 2017
2016
Axiogenesis and Metrion announce stem cell collaboration
7th November 2016
Metrion Expands Operations
17th October 2016
Metrion Biosciences Joins CRACK IT “DRGNET” Human Pain Research Consortium
23rd August 2016
Axol Bioscience and Metrion Biosciences Announce Research Collaboration to Study Human Stem Cell-Derived Cardiomyocytes for Cardiac Safety and Drug Discovery Applications
26th July 2016
Metrion Biosciences receives funding to work on human stem cell-derived iPS cardiomyocytes to create better cardiac safety assays
21st March 2016
2015
Metrion Biosciences becomes an independent CRO
22nd October 2015
Xention introduces Metrion Biosciences, a Specialist Ion Channel Screening Business
13th May 2015
More information: www.metrionbiosciences.com
Follow us on:
LinkedIn: Metrion Biosciences
Twitter: @Metrion_Biosci
Let’s work together
What are your specific ion channel and assay needs?
If you have any questions or would to like discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.